Diagnostic Utility of Galectin-3 in Thyroid Cancer

Overview

Journal Am J Pathol

Publisher Elsevier

Specialty Pathology

Date 2010 Apr 6

PMID 20363921

Citations 55

Authors

Connie G Chiu

Scott S Strugnell

Obi L Griffith

Steven J M Jones

Allen M Gown

Blair Walker

Ivan R Nabi

Sam M Wiseman

Affiliations

Soon will be listed here.

Abstract

Galectin-3 (Gal-3), which has received significant recent attention for its utility as a diagnostic marker for thyroid cancer, represents the most well-studied molecular candidate for thyroid cancer diagnosis. Gal-3 is a protein that binds to beta-galactosidase residues on cell surface glycoproteins and has also been identified in the cytoplasmic and nuclear compartment. This marker has been implicated in regulation of normal cellular proliferation and apoptosis, as well as malignant transformation and the metastasis of cancer cells. We here present a mechanistic review of Gal-3 and its role in cancer development and progression. Gal-3 expression studies in thyroid tissue and cytologic tumor specimens and their methodological considerations are also discussed in this article. Despite great variance in their methodology, the majority of immunohistochemical studies found that Gal-3 was differentially expressed in thyroid carcinoma compared with benign and normal thyroid specimens, suggesting that Gal-3 is a good diagnostic marker for thyroid cancer. Recent studies have also demonstrated improved methodological reliability. On the other hand, Gal-3 genomic expression studies have shown inconsistent results for diagnostic utility and are not recommended. Overall, the development of Gal-3 as a diagnostic marker for thyroid cancer represents a promising avenue for future study, and its clinical application could significantly reduce the number of diagnostic thyroid operations performed for cases of indeterminant fine needle aspiration biopsy cytology, and thus positively impact the current management of thyroid nodular disease.

Citing Articles

Decreased circulating levels of angiopoietin - 1 (Ang-1) are associated with the presence of multinodular goiter or differentiated thyroid cancer.

Nixon A, Provatopoulou X, Kalogera E, Bletsa G, Zografos G, Bouklas D Surg Pract Sci. 2025; 13():100176.

PMID: 39845393 PMC: 11750009. DOI: 10.1016/j.sipas.2023.100176.

New Horizons of Biomarkers in Metastatic Thyroid Cancer.

Cendra A, Pekarek L, Pedrejon B, Bernier L, Cervantes E, Cendra C J Cancer. 2025; 16(1):241-264.

PMID: 39744583 PMC: 11660124. DOI: 10.7150/jca.101395.

The Unappreciated Value of a Cheap, 'Good Enough' Method of Detecting Thyroid Cancer.

Sciacchitano S, Rugge M, Bartolazzi A J Clin Med. 2024; 13(23).

PMID: 39685748 PMC: 11642387. DOI: 10.3390/jcm13237290.

Uncovering key molecular mechanisms in the early and late-stage of papillary thyroid carcinoma using association rule mining algorithm.

Hosseiniyan Khatibi S, Zununi Vahed S, Homaei Rad H, Emdadi M, Akbarpour Z, Teshnehlab M PLoS One. 2023; 18(11):e0293335.

PMID: 37917782 PMC: 10621943. DOI: 10.1371/journal.pone.0293335.

Thyroid Nodules: Emerging Trends in Detection and Visualization based on Citespace.

Yao W, Peng X, Guan Y, Du X, Xia C, Liu F Endocr Metab Immune Disord Drug Targets. 2023; 24(1):130-141.

PMID: 37608676 PMC: 10909822. DOI: 10.2174/1871530323666230822143549.

References

Liu Y, Morreau H, Kievit J, Romijn J, Carrasco N, Smit J . Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of.... Eur J Endocrinol. 2008; 158(3):375-84. DOI: 10.1530/EJE-07-0492. View

Prasad M, Pellegata N, Huang Y, Nagaraja H, de la Chapelle A, Kloos R . Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol. 2004; 18(1):48-57. DOI: 10.1038/modpathol.3800235. View

Takano T, Miyauchi A, Yoshida H, Kuma K, Amino N . Decreased relative expression level of trefoil factor 3 mRNA to galectin-3 mRNA distinguishes thyroid follicular carcinoma from adenoma. Cancer Lett. 2005; 219(1):91-6. DOI: 10.1016/j.canlet.2004.07.004. View

Giannini R, Faviana P, Cavinato T, Elisei R, Pacini F, Berti P . Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens. Thyroid. 2003; 13(8):765-70. DOI: 10.1089/105072503768499662. View

Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim H, Raz A . Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem. 2001; 277(9):6852-7. DOI: 10.1074/jbc.M107668200. View

Pulcrano M, Boukheris H, Talbot M, Caillou B, Dupuy C, Virion A . Poorly differentiated follicular thyroid carcinoma: prognostic factors and relevance of histological classification. Thyroid. 2007; 17(7):639-46. DOI: 10.1089/thy.2007.0029. View

Takenaka Y, Inohara H, Yoshii T, Oshima K, Nakahara S, Akahani S . Malignant transformation of thyroid follicular cells by galectin-3. Cancer Lett. 2003; 195(1):111-9. DOI: 10.1016/s0304-3835(03)00056-9. View

Beesley M, McLaren K . Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology. 2002; 41(3):236-43. DOI: 10.1046/j.1365-2559.2002.01442.x. View

Franco C, Martinez V, Allamand J, Medina F, Glasinovic A, Osorio M . Molecular markers in thyroid fine-needle aspiration biopsy: a prospective study. Appl Immunohistochem Mol Morphol. 2009; 17(3):211-5. DOI: 10.1097/PAI.0b013e31818935a9. View

10.

Martins L, Matsuo S, Ebina K, Kulcsar M, Friguglietti C, Kimura E . Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. J Clin Endocrinol Metab. 2002; 87(10):4806-10. DOI: 10.1210/jc.2002-020094. View

11.

Yang R, Hsu D, Liu F . Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci U S A. 1996; 93(13):6737-42. PMC: 39096. DOI: 10.1073/pnas.93.13.6737. View

12.

Kim M, Kim H, Hong S, Shong Y, Gong G . Diagnostic utility of galectin-3 in aspirates of thyroid follicular lesions. Acta Cytol. 2006; 50(1):28-34. DOI: 10.1159/000325891. View

13.

Davidson P, Davis M, Patterson R, Ripoche M, Poirier F, Wang J . Shuttling of galectin-3 between the nucleus and cytoplasm. Glycobiology. 2002; 12(5):329-37. DOI: 10.1093/glycob/12.5.329. View

14.

de Matos P, Ferreira A, de Oliveira Facuri F, Assumpcao L, Metze K, Ward L . Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology. 2005; 47(4):391-401. DOI: 10.1111/j.1365-2559.2005.02221.x. View

15.

Carpi A, Nicolini A, Marchetti C, Iervasi G, Antonelli A, Carpi F . Percutaneous large-needle aspiration biopsy histology of palpable thyroid nodules: technical and diagnostic performance. Histopathology. 2007; 51(2):249-57. DOI: 10.1111/j.1365-2559.2007.02764.x. View

16.

Califice S, Castronovo V, Bracke M, van den Brule F . Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene. 2004; 23(45):7527-36. DOI: 10.1038/sj.onc.1207997. View

17.

Takano T, Miyauchi A, Matsuzuka F, Yoshida H, Kuma K, Amino N . Ubiquitous expression of galectin-3 mRNA in benign and malignant thyroid tumors. Cancer Lett. 2003; 199(1):69-73. DOI: 10.1016/s0304-3835(03)00343-4. View

18.

Partridge E, Le Roy C, Di Guglielmo G, Pawling J, Cheung P, Granovsky M . Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science. 2004; 306(5693):120-4. DOI: 10.1126/science.1102109. View

19.

Maruta J, Hashimoto H, Yamashita H, Yamashita H, Noguchi S . Immunostaining of galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma. Diagn Cytopathol. 2004; 31(6):392-6. DOI: 10.1002/dc.20156. View

20.

Inohara H, Segawa T, Miyauchi A, Yoshii T, Nakahara S, Raz A . Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies. Biochem Biophys Res Commun. 2008; 376(3):605-10. DOI: 10.1016/j.bbrc.2008.09.041. View